Biocrucible

Biocrucible, headquartered at Granta Park in Cambridge, is applying its novel proprietary molecular technology platform to enhance and accelerate the behavior and kinetics of engineered biological systems. Biocrucible's technology can significantly improve the performance of many processes currently used across the life sciences and diagnostics industries, and Biocrucible anticipates novel applications as well. Biocrucible aims to launch life science tools and other products in the near future to add value to existing workflows before developing entirely new applications.Biocrucible combines experienced R&D scientists, biotechnology management, and outstanding creativity. The company was founded by Dr. Niall Armes, the inventor of Recombinase Polymerase Amplification (RPA) isothermal DNA amplification technology. Niall leads the research, and the company is assembling all the components to ensure strong growth and success in a broad and valuable market.Biocrucible is currently collaborating with the Gates Foundation to research rapid molecular testing methods for COVID-19 and other pathogens that can be used in home or field settings.